Biologics, Bulls, and Billion‑Dollar Plus Bets: AbbVie’s Immunology $10.9B ‘Durability’ Shopping Spree Explained -( $ABBV $APGE $EPRX $REGN $SNY ) by John F. Heerdink, Jr. June 22, 2026 254Views 0Likes AbbVie’s latest deal signals that Big Pharma’s appetite for next‑gen immunology assets is not just alive, it is visibly bulking up for the long haul, and investors who ignore this corner of the market may find themselves benched just as the real… Read more
